BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Core Points - BioLineRx Ltd. will release its unaudited financial results for Q3 2025 on November 24, 2025, before U.S. markets open [1] - A conference call will be held at 8:30 a.m. EST featuring remarks by CEO Philip Serlin [2] Company Overview - BioLineRx Ltd. is a biopharmaceutical company focused on developing therapies in oncology and rare diseases [4] - The company's first approved product is APHEXDA® (motixafortide), indicated for stem cell mobilization in multiple myeloma, commercialized by Ayrmid Ltd. globally (except Asia) and Gloria Biosciences in Asia [4] - BioLineRx retains rights to develop motixafortide for metastatic pancreatic cancer (PDAC) and is conducting a Phase 2b trial in collaboration with Columbia University [4] - The company has a joint venture with Hemispherian AS to develop GLIX1, an oral small molecule targeting DNA damage response in glioblastoma and other solid tumors, with a Phase 1/2a clinical trial planned for Q1 2026 [5]